These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37442486)

  • 1. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
    Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
    Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
    Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
    Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
    Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
    Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptides as co-formers in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
    Wu W; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
    Wang Y; Grohganz H; Rades T
    Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
    Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microfibrous Solid Dispersions of Poorly Water-Soluble Drugs Produced via Centrifugal Spinning: Unexpected Dissolution Behavior on Recrystallization.
    Marano S; Barker SA; Raimi-Abraham BT; Missaghi S; Rajabi-Siahboomi A; Aliev AE; Craig DQM
    Mol Pharm; 2017 May; 14(5):1666-1680. PubMed ID: 28296409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
    Fael H; Demirel AL
    Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin?
    França MT; Marcos TM; Pereira RN; Stulzer HK
    Eur J Pharm Sci; 2020 Feb; 143():105178. PubMed ID: 31812717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior.
    Holzapfel K; Liu J; Rades T; Leopold CS
    Int J Pharm; 2022 Mar; 616():121552. PubMed ID: 35131351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
    Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
    AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
    Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.